Which subgroups of patients benefit most from a Ven+Aza combination?

During the 2021 ASCO Annual Meeting, the MDS Hub spoke with Pierre Fenaux, Hôpital Saint-Louis, Paris, FR. We asked, Which subgroups of patients benefit most from a Venetoclax+Azacitidine (Ven+Aza) combination?

Fenaux explains the current use for Ven+Aza before outlining early efficacy data from trials investigating this combination for high-risk MDS, highlighting the effect on earlier response rates and preventing later myelosuppression. He then suggests further stratification of this subgroup, including karyotype and transplant eligibility. Finally, he proposes the possibility for new combination therapies to improve survival in MDS.